38.28 USD
+0.47 (+1.24%)
IBEX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 85 industry peers in the IT Services industry. IBEX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IBEX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make IBEX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year IBEX was profitable.
IBEX had a positive operating cash flow in the past year.
IBEX had positive earnings in each of the past 5 years.
Each year in the past 5 years IBEX had a positive operating cash flow.
1.2 Ratios
IBEX has a Return On Assets of 14.58%. This is amongst the best in the industry. IBEX outperforms 92.94% of its industry peers.
IBEX has a better Return On Equity (28.81%) than 91.76% of its industry peers.
With an excellent Return On Invested Capital value of 21.63%, IBEX belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.58% | ||
| ROE | 28.81% | ||
| ROIC | 21.63% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IBEX has a better Profit Margin (7.14%) than 72.94% of its industry peers.
IBEX's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 9.18%, IBEX is in the better half of the industry, outperforming 67.06% of the companies in the same industry.
IBEX's Operating Margin has improved in the last couple of years.
IBEX has a Gross Margin (30.62%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of IBEX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.18% | ||
| PM (TTM) | 7.14% | ||
| GM | 30.62% |
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IBEX is creating value.
IBEX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IBEX has an Altman-Z score of 5.32. This indicates that IBEX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.32, IBEX is in the better half of the industry, outperforming 77.65% of the companies in the same industry.
IBEX has a debt to FCF ratio of 0.05. This is a very positive value and a sign of high solvency as it would only need 0.05 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.05, IBEX belongs to the best of the industry, outperforming 92.94% of the companies in the same industry.
IBEX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.01, IBEX belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.05 | ||
| Altman-Z | 5.32 |
ROIC/WACC2.39
WACC9.04%
2.3 Liquidity
IBEX has a Current Ratio of 1.82. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
IBEX's Current ratio of 1.82 is in line compared to the rest of the industry. IBEX outperforms 55.29% of its industry peers.
A Quick Ratio of 1.82 indicates that IBEX should not have too much problems paying its short term obligations.
IBEX's Quick ratio of 1.82 is in line compared to the rest of the industry. IBEX outperforms 55.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
IBEX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.96%, which is quite impressive.
The Earnings Per Share has been growing by 41.04% on average over the past years. This is a very strong growth
IBEX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.86%.
The Revenue has been growing slightly by 6.62% on average over the past years.
EPS 1Y (TTM)41.96%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%73.08%
Revenue 1Y (TTM)12.86%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.55%
3.2 Future
The Earnings Per Share is expected to grow by 13.72% on average over the next years. This is quite good.
Based on estimates for the next years, IBEX will show a quite strong growth in Revenue. The Revenue will grow by 9.19% on average per year.
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.81%
Revenue Next 2Y9.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.04, IBEX is valued correctly.
Based on the Price/Earnings ratio, IBEX is valued cheaply inside the industry as 87.06% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.22, IBEX is valued rather cheaply.
IBEX is valuated reasonably with a Price/Forward Earnings ratio of 10.57.
Based on the Price/Forward Earnings ratio, IBEX is valued cheaper than 89.41% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.58. IBEX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.04 | ||
| Fwd PE | 10.57 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IBEX is valued cheaply inside the industry as 88.24% of the companies are valued more expensively.
65.88% of the companies in the same industry are more expensive than IBEX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.53 | ||
| EV/EBITDA | 6.93 |
4.3 Compensation for Growth
IBEX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of IBEX may justify a higher PE ratio.
IBEX's earnings are expected to grow with 13.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.52
PEG (5Y)0.29
EPS Next 2Y13.72%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IBEX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:IBEX (12/18/2025, 12:06:08 PM)
38.28
+0.47 (+1.24%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)
Earnings (Next)
Inst Owners94.03%
Inst Owner Change-3.84%
Ins Owners2.88%
Ins Owner Change-0.15%
Market Cap515.63M
Revenue(TTM)579.74M
Net Income(TTM)41.38M
Analysts45.71
Price Target39.78 (3.92%)
Short Float %1.13%
Short Ratio1.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.95%
Min EPS beat(2)20.05%
Max EPS beat(2)21.85%
EPS beat(4)4
Avg EPS beat(4)16.83%
Min EPS beat(4)10.89%
Max EPS beat(4)21.85%
EPS beat(8)7
Avg EPS beat(8)12.58%
EPS beat(12)10
Avg EPS beat(12)14.59%
EPS beat(16)12
Avg EPS beat(16)13.3%
Revenue beat(2)2
Avg Revenue beat(2)5.51%
Min Revenue beat(2)2.5%
Max Revenue beat(2)8.52%
Revenue beat(4)4
Avg Revenue beat(4)4.65%
Min Revenue beat(4)2.45%
Max Revenue beat(4)8.52%
Revenue beat(8)5
Avg Revenue beat(8)1.79%
Revenue beat(12)5
Avg Revenue beat(12)-0.35%
Revenue beat(16)7
Avg Revenue beat(16)-0.06%
PT rev (1m)1.3%
PT rev (3m)1.3%
EPS NQ rev (1m)-2.48%
EPS NQ rev (3m)-1.26%
EPS NY rev (1m)5.47%
EPS NY rev (3m)10.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)1.82%
Revenue NY rev (3m)1.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.04 | ||
| Fwd PE | 10.57 | ||
| P/S | 0.89 | ||
| P/FCF | 16.53 | ||
| P/OCF | 9.62 | ||
| P/B | 3.59 | ||
| P/tB | 3.91 | ||
| EV/EBITDA | 6.93 |
EPS(TTM)3.18
EY8.31%
EPS(NY)3.62
Fwd EY9.46%
FCF(TTM)2.32
FCFY6.05%
OCF(TTM)3.98
OCFY10.39%
SpS43.04
BVpS10.66
TBVpS9.78
PEG (NY)0.52
PEG (5Y)0.29
Graham Number27.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.58% | ||
| ROE | 28.81% | ||
| ROCE | 26.64% | ||
| ROIC | 21.63% | ||
| ROICexc | 24.4% | ||
| ROICexgc | 26.15% | ||
| OM | 9.18% | ||
| PM (TTM) | 7.14% | ||
| GM | 30.62% | ||
| FCFM | 5.38% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.05 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 129.83% | ||
| Cap/Sales | 3.86% | ||
| Interest Coverage | 31.53 | ||
| Cash Conversion | 76.01% | ||
| Profit Quality | 75.39% | ||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z | 5.32 |
F-Score8
WACC9.04%
ROIC/WACC2.39
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.96%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%73.08%
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.86%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.55%
Revenue Next Year12.81%
Revenue Next 2Y9.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.48%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year68.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.26%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y19.11%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%
IBEX LTD / IBEX FAQ
Can you provide the ChartMill fundamental rating for IBEX LTD?
ChartMill assigns a fundamental rating of 7 / 10 to IBEX.
Can you provide the valuation status for IBEX LTD?
ChartMill assigns a valuation rating of 8 / 10 to IBEX LTD (IBEX). This can be considered as Undervalued.
What is the profitability of IBEX stock?
IBEX LTD (IBEX) has a profitability rating of 7 / 10.
Can you provide the financial health for IBEX stock?
The financial health rating of IBEX LTD (IBEX) is 7 / 10.
Can you provide the expected EPS growth for IBEX stock?
The Earnings per Share (EPS) of IBEX LTD (IBEX) is expected to grow by 22.95% in the next year.